Price (90d)
$52.92Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-377.94M | $-3.29 |
| 2024 | $0.00 | $-246.29M | $-2.47 |
| 2023 | $0.00 | $-165.79M | $-1.99 |
| 2022 | $33.19M | $-134.50M | $-2.21 |
| 2021 | $18.82M | $-131.80M | $-3.59 |
Social Signal Score
Earnings
Fri, Nov 13(in 3 months)
Consensus estimate $-0.87 per share
Typical surprise -1.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.84 vs $-0.84beat
- Thu, May 7$-0.83 vs $-0.82miss
- Tue, Mar 3$-0.88 vs $-0.88beat
- Fri, Nov 14$-0.90 vs $-0.84miss
- Wed, Aug 6$-0.98 vs $-0.66miss
- Wed, May 14$-0.67 vs $-0.63miss
Estimates and results for SRRK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
SRRKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsbusinesswire.com·7d ago·Neutral
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today a
View source ↗